MedMira (MedMira) Price-to-Tangible-Book : (As of May. 22, 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Price-to-Tangible-Book?

As of today (2024-05-22), MedMira's share price is $0.06. MedMira's Tangible Book per Share of Jan. 2024 for the quarter that ended in Jan. 2024 was $-0.02. Hence, MedMira's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for MedMira's Price-to-Tangible-Book or its related term are showing as below:

MMIRF's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.78
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, MedMira's share price is $0.06. MedMira's Book Value per Sharefor the quarter that ended in Jan. 2024 was $-0.02. Hence, MedMira's P/B Ratio of today is .

MedMira Price-to-Tangible-Book Historical Data

The historical data trend for MedMira's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Price-to-Tangible-Book Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Price-to-Tangible-Book

Get a 7-Day Free Trial

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MedMira's Price-to-Tangible-Book

For the Biotechnology subindustry, MedMira's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where MedMira's Price-to-Tangible-Book falls into.

MedMira Price-to-Tangible-Book Calculation

MedMira's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jan. 2024 )
	=	0.06	/	-0.017
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

MedMira Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of MedMira's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.